Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

NCT03596476 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-05-03
Last updated
2024-06-26

Condition(s) studied

Gastro-esophageal Reflux Disease

Investigational drug(s) / intervention(s)

Upper gastrointestinal (GI) endoscopyWireless pH monitoringPost prandial esophageal High Resolution Impedance ManometrypH-impedance monitoring

Upper gastrointestinal (GI) endoscopy: An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.

Wireless pH monitoring: Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).

Post prandial esophageal High Resolution Impedance Manometry: Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.

pH-impedance monitoring: 24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).

Study summary

Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH \< 4. Another method of reflux detection is based on liquid and gas detection in the esophagus using pH-impedance monitoring. Recently the combination of impedance and esophageal pressure monitoring, called esophageal high resolution impedance manometry (HRIM) was introduced to simultaneously identify reflux episodes and their mechanisms. It has several advantages over esophageal pH measurement: shorter recording duration (1 or 2 hours post prandial) and identification of reflux mechanisms that might guide the choice of the best therapeutic option.

Hypothesis: The 1-hour post prandial esophageal HRIM might be useful to diagnose GERD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient older than 18 years * Typical symptoms of GERD (heartburn, regurgitation) at least twice a week despite PPI therapy for at least one month. * Reflux Disease Questionnaire (RDQ) score off PPI \> 3 * Subject with health insurance Exclusion Criteria: * Previous esophago-gastric surgery, * Previous history of developing esophageal or gastric tumor, esophageal stricture, or esophageal varices * Pregnancy (assessment at V0) * Contraindication to general anesthesia, * Contraindications to the wireless capsule pH-monitoring: pacemakers, implantable cardiac defibrillator, * Contraindications to HRIM: inability to tolerate nasal intubation, significant bleeding disorders for which nasal intubation is contraindicated, known esophageal obstruction is preventing the passage of the HRIM probe. * Intolerance or allergy to one component of the test meal, * Intolerance or allergy to PPI, * Inability to give consent, * Mentally unbalanced patients, under supervision or guardianship * Decline to participate in the study, * Participation in another study at the same time

Primary outcome measure(s)

  • Number of reflux episodes identified on the post prandial HRIM — 1 hour after the end of the meal
    The diagnostic performance of the number of reflux episodes measured by 1-hour post prandial HRIM will be evaluated by estimating the Area Under the ROC Curve and its 95% confidence interval. The gold standard to define GERD will be based on esophageal pH measurements with capsule (GERD is defined as acid exposure time (AET; percentage of total time with esophageal pH \< 4) greater than 6% for at least one day on wireless pH monitoring).

Trial sites (7)

FacilityCityRegionStatus
Service d'Hepato-Gastroenterologie - Hôpital Trousseau - CHU de Tours Chambray-lès-Tours France Recruiting
Service d'Hepato-Gastroenterologie - Hôpital Louis Mourier - APHP Colombes France Recruiting
Service d'Explorations Fonctionnelles Digestives - Hôpital Edouard Herriot - HCL Lyon France Recruiting
Service d'Hepato-Gastroenterologie - Hôtel Dieu - CHU de Nantes Nantes France Recruiting
Service d'Hepato-Gastroenterologie - Hôpital Haut Lévêque - CHU de Bordeaux Pessac France Recruiting
Service d'Hepato-Gastroenterologie - Hôpital Pontchaillou- CHU de Rennes Rennes France Recruiting
Service de Physiologie Digestive, Respiratoire, Urinaire et Sportive - CHU de Rouen Rouen France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03596476 on ClinicalTrials.gov ↗ ← All trials in France